

under the aegis of



UNIVERSITÀ
DEGLI STUDI
DI MILANO

cover picture: "Chiostro d'Onore" University of Milan



DAAs for the treatment of chronic hepatitis C:
translating efficacy into effectiveness

Milan ▪ 2,3 July 2012

Palazzo Visconti

MEETING AIM

In the last year the therapeutic scenario of chronic hepatitis C has been subverted by the introduction of HCV protease inhibitors, that in combination with pegylated interferon plus ribavirin have become the standard of care treatment for patients with genotype 1 infection. Due to specific protease inhibitors related side effects and treatment algorithms that are far from being user-friendly, this important clinical breakthrough has increased the complexity in the clinical management of HCV-1 patients. Moreover there are still some areas of uncertainties that regard both the selection of patients for treatment as well as the optimal management of protease inhibitors based regimens. The present workshop aims to highlight these grey areas with the ultimate aim of translating treatment efficacy as seen in clinical trials, into effectiveness in the clinical practice. A panel of opinion leaders from Europe and the US will discuss these issues with specific lectures and case presentations followed by interactive discussion. We do hope that everybody will enjoy attending this meeting while providing his/her fruitful contribution in the discussion between panelists and audience.

STEERING COMMITTEE

Massimo Colombo

Alessio Aghemo

U.O. Gastroenterologia

Fondazione IRCCS Ca' Granda

Ospedale Maggiore Policlinico

Via Francesco Sforza, 35 - Milan (IT)

Ph. +39 (0)2 55035432

alessio.aghemo@unimi.it

DAAs for the treatment of chronic hepatitis C:
translating efficacy into effectiveness

FACULTY

Nezam Afdhal

Professor of Medicine

Beth Israel Deaconess Medical Center, Boston (MA, USA)

Alessio Aghemo

Dept. of Medicine

Fondazione IRCCS Ca' Granda

Ospedale Maggiore Policlinico, Milan (IT)

Alfredo Alberti

Dept. of Histology, Microbiology and Medical Biotechnology

University of Padua (IT)

Ferruccio Bonino

Dept. of Internal Medicine

University of Pisa (IT)

Maurizia Brunetto

Dept. of Hepatology

Azienda Ospedaliero Universitaria Pisana (IT)

Stéphane Chevaliez

Dept. of Virology, French National Reference Center

for Viral Hepatitis B, C and delta

INSERM U955, Henri Mondor University Hospital, Créteil (FR)

Alessia Ciancio

Dept. of Gastroenterology

San Giovanni Battista Hospital, Turin (IT)

Massimo Colombo

Dept. of Medicine

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

University of Milan (IT)

Antonio Craxì

Gastroenterology and Hepatology, DIBIMIS

Policlinico Paolo Giaccone

University of Palermo (IT)

Vito Di Marco

Gastroenterology and Hepatology, DIBIMIS

Policlinico Paolo Giaccone

University of Palermo (IT)

Philippe Halfon

Virology and Infectious Diseases

Hôpital Ambroise Pare, Marseille (FR)

Alessandra Mangia

Dept. of Hepatology

IRCCS Ospedale Casa Sollievo della Sofferenza

San Giovanni Rotondo (IT)

Patrick Marcellin

Professor of Hepatology

Hôpital Beaujon, Clichy (FR)

Mario Rizzetto

Dept. of Gastroenterology

Ospedale San Giovanni Battista

University of Turin (IT)

Maria Grazia Rumi

Dept. of Hepatology

Ospedale San Giuseppe

University of Milan (IT)

Christoph Sarrazin

Dept. of Internal Medicine

J.W. Goethe University Hospital, Frankfurt (DE)

Giovanni Squadrito

Unit of Clinical and Molecular Hepatology

Dept. of Internal Medicine

University of Messina (IT)

**DAA's for the treatment of chronic hepatitis C:
translating efficacy into effectiveness**

13.00-14.00

Welcome Lunch

14.00-14.20

Meeting Introduction

Massimo Colombo

14.20-14.50

Standard of care therapy in 2012

Alfredo Alberti

Chairmen: *Ferruccio Bonino, Antonio Craxì*

14.50-15.20

From Guidelines to clinical practice

Antonio Craxì

15.20-15.50

IL28B genotype: useful or not useful?

Stéphane Chevaliez

Monday, July 2

15.50-16.20

Management of specific side effects of DAAs

Nezam Afdhal

16.20-17.20

Discussion

17.20-17.40

Coffee Break

17.40-19.00

Case presentations with discussion

Alessia Ciancio, Vito Di Marco

**DAA's for the treatment of chronic hepatitis C:
translating efficacy into effectiveness**

Chairmen: *Massimo Colombo, Mario Rizzetto*

09.00-09.30

**Resistance to DAAs: are there any
clinical implications?**

Philippe Halfon

09.30-10.00

DAAs in patients with cirrhosis

Alessandra Mangia

10.00-10.30

Discussion

10.30-10.50

Coffee break

10.50-12.20

Case Presentations with discussion

Alessio Aghemo, Giovanni Squadrito

12.20-14.00

Lunch

Tuesday, July 3

Chairmen: *Massimo Colombo, Patrick Marcellin*

14.00-14.30

**Future therapies for HCV- 1:
between myth and reality**

Christoph Sarrazin

14.30-15.00

**Future therapies for other
HCV genotypes**

Patrick Marcellin

15.00-15.30

Discussion

15.30-17.00

Case Presentations with discussion

Maurizia Brunetta, Maria Grazia Rumi

GENERAL INFORMATION

MEETING VENUE

Palazzo Visconti
Via Cino del Duca, 8 - Milan (IT)

REGISTRATION

Free-registration for a fixed number participants. Online registration available on the website www.iec-srl.it, section "Events" and then selecting "Application Form". A few delegates will be invited directly by the sponsor.

CME CREDITS

PROVIDER ITALIAN CME CREDITS: I&C srl (n. 1740)

ID CME ITALIAN CREDITS: 34312

CME CREDITS: n. 7,5

CME credits for physicians have been requested, to be obtained by attending all sessions of the meeting (100% of attendance). Disciplines: Gastroenterology, Infectious Diseases, Internal Medicine, General Medicine.

Checking Method: Multiple-choice test (75% of the answers must be correct).

I&C S.r.l. assumes all responsibility for the content, quality and ethical correctness of this CME activity.



FOR FURTHER INFORMATION

ORGANIZING SECRETARIAT

I&C I&C srl
Via Andrea Costa, 202/6
40134 Bologna (IT)
Ph. +39 (0)51 6144004
Fax +39 (0)51 6142772
e-mail: federica.schiassi@iec-srl.it
web: www.iec-srl.it

 **MSD** with unrestricted contribution of
MSD ITALIA S.R.L. www.msd-italia.it